Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

milademetan × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Lymphoid 1 Head & Neck 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 646 Paclitaxel 617 Cyclophosphamide 571 Docetaxel 501 Capecitabine 447 Letrozole 387 Fulvestrant 353 Carboplatin 347 Doxorubicin 304 Tamoxifen 277 Anastrozole 241 pembrolizumab 239 exemestane 224 Radiotherapy 221 Epirubicin 215 Bevacizumab 201 pertuzumab 198 palbociclib 196 Gemcitabine 191 Vinorelbine 183 Lapatinib 169 Magnetic Resonance Spectroscopy 154 130-nm albumin-bound paclitaxel 153 Albumin-Bound Paclitaxel 142 eribulin 139 Surveys and Questionnaires 136 Exercise 132 Drug Therapy 119 Taxes 116 Fluorouracil 116

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡